email article The Pfizer/BioNTech COVID-19 vaccine should be offered to adults ages 16 and older under the FDA's emergency use authorization (EUA), said the CDC Advisory Committee on Immunization Practices (ACIP) in an emergency meeting on Saturday. In a 11-0-3 vote (with three members recusing themselves due to conflicts of interest), the committee voted for this interim recommendation. They also voted 14-0 to amend the adult and child/adolescent immunization schedule to recommend COVID-19 vaccination under the scope of use for an EUA. CDC staff noted that insurance carriers will have 15 business days after the vote and adoption until they will be mandated to cover COVID-19 vaccine administration fees. They said the generic language about COVID-19 vaccines, rather than the Pfizer vaccine, is to ensure there is no delay in coverage as additional vaccines are added.